BEYOND Pilot Study
Public ClinicalTrials.gov record NCT00893217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to valuate safety and tolerability of Betaseron.
Study identification
- NCT ID
- NCT00893217
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2002
- Primary completion
- Not listed
- Completion
- May 31, 2003
- Last update posted
- Nov 8, 2009
2002 – 2003
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Washington D.C. | District of Columbia | 20037 | — |
| Not listed | Atlanta | Georgia | 30309-1465 | — |
| Not listed | Chicago | Illinois | 60637-1470 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Louisville | Kentucky | 40205 | — |
| Not listed | Ann Arbor | Michigan | 48109-0330 | — |
| Not listed | Reno | Nevada | 89557-0035 | — |
| Not listed | Stony Brook | New York | 11794 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | High Point | North Carolina | 27262 | — |
| Not listed | Winston-Salem | North Carolina | 27157-1009 | — |
| Not listed | Columbus | Ohio | 43210-1240 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00893217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2009 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00893217 live on ClinicalTrials.gov.